Why Sunshine Heart’s Enrollment Issues Are Concerning
Research - Sunshine Heart's (SSH) fourth quarter call was revealing regarding ongoing enrollment problems. Read on to get our take.
Premium: Read NowResearch
It’s Time to Own Durect – Again
Research - With the stock hitting previous support, we think its time to own Durect (DRRX) yet again.
Premium: Read Now
Investors Have Overlooked the Bottom Line Potential With This Nutraceutical Business
Research - Forward earnings potential drastically undervalued and could mean upside into the double digits for the long-term investor. Stock traded at $4-5 before key negative inflection … Continue Reading
Premium: Read Now
Events Aligned for Alcobra in 2014 But There’s More to the Story
Research - Alcobra Ltd. (ADHD) is a clinical stage biopharmaceutical company that was founded in 2008 and hit the public stage in 2013. Alcobra currently trades at … Continue Reading
Premium: Read Now
Why Progenics Should Be Back on the Sidelines
Insights - Two weeks ago with the release of data from an ongoing phase 2 study of the company’s oncology candidate, PSMA ADC, shares of Progenics Pharmaceuticals (PGNX) took … Continue Reading
Premium: Read Now
BioDelivery Data Release Removes An Overhang
Research - BioDelivery Sciences (BDSI) and partner Endo Health Solutions (ENDP) announced on the 23rd that the second of three phase 3 trials testing one of its lead drug candidates, BEMA buprenorphine, … Continue Reading
Read Now
Incyte Continues Building on a Successful 2013
Research - Incyte (INCY) has been one of PropThink’s most profitable recommendations in the last year, with shares rising over 187% since our July 2013 initiation of … Continue Reading
Premium: Read Now